Fulton Breakefield Broenniman buys $7,084,442 stake in Amgen (AMGN)

Amgen (AMGN) : Fulton Breakefield Broenniman scooped up 162 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 40,849 shares of Amgen which is valued at $7,084,442.Amgen makes up approximately 1.42% of Fulton Breakefield Broenniman’s portfolio.

Other Hedge Funds, Including , Montag A Associates Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 460 additional shares and now holds a total of 3,495 shares of Amgen which is valued at $606,138. Amgen makes up approx 0.08% of Montag A Associates Inc’s portfolio.Clarivest Asset Management boosted its stake in AMGN in the latest quarter, The investment management firm added 48,271 additional shares and now holds a total of 386,472 shares of Amgen which is valued at $66,484,778. Amgen makes up approx 1.89% of Clarivest Asset Management’s portfolio.Atria Investments reduced its stake in AMGN by selling 175 shares or 2.54% in the most recent quarter. The Hedge Fund company now holds 6,707 shares of AMGN which is valued at $1,076,608. Amgen makes up approx 0.11% of Atria Investments’s portfolio.Fragasso Group boosted its stake in AMGN in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 20,432 shares of Amgen which is valued at $3,279,745. Amgen makes up approx 1.20% of Fragasso Group’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in AMGN in the latest quarter, The investment management firm added 221,118 additional shares and now holds a total of 1,175,040 shares of Amgen which is valued at $189,298,944. Amgen makes up approx 0.84% of Bnp Paribas Arbitrage Sa’s portfolio.

Amgen closed down -1.32 points or -0.76% at $172.34 with 27,06,525 shares getting traded on Monday. Post opening the session at $173.31, the shares hit an intraday low of $171.83 and an intraday high of $174.16 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Investors should note that on Jul 22, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced Aug 15, 2016 as the ex-dividend date and fixed the record date on Aug 17, 2016. The payable date has been fixed on Sep 8, 2016.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.